James M. Tepper

Neuroscience · Life Sciences

54h-index9.7kcitations156works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(89), Neurotransmitter Receptor Influence on Behavior(40), Neural dynamics and brain function(37), Receptor Mechanisms and Signaling(33), PARP inhibition in cancer therapy(24)

Publications156 total

p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors
Cancer Cell·2026
Abstract C105: Gain of function cDNA screen identifies SIK3 activation as a therapeutic strategy for STK11 mutant cancer
Molecular Cancer Therapeutics·2025
Temporal control of sgRNA library activation unlocks large-scale <i>in vivo</i> CRISPR screens
2025Open Access
Abstract C048: Inducible activation of sgRNA libraries in tumor xenografts empowers large-scale in vivo target discovery screens
Molecular Cancer Therapeutics·2023
Abstract B098: Unbiased in vitro and in vivo drug anchor screens identify mechanisms of resistance and sensitization for MTA-cooperative PRMT5 inhibitors in MTAP-deleted cancer models
Molecular Cancer Therapeutics·2023
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Tibor Koós(18), Fatuel Tecuapetla(7), Osvaldo Ibáñez-Sandoval(6), Fulva Shah(6), Maxime Assous(6), Christian Lee(5), Francine Trent(5), Giannicola Genovese(4), Carlos A. Paladini(4), J. Paul Bolam(3), Charles J. Wilson(3), Karl Deisseroth(3), Thomas W. Faust(3), Li Li(3), Lynda Chin(3), Alessandro Carugo(3), Andrea Viale(3), Frederick S. Robinson(3), Anirban Maitra(3), Timothy P. Heffernan(3)